TABLE 1.

Demographics of Subjects

Subject no.	Sex	Age (y)	Cohort	Injected dose (MBq)	β-amyloid status (visual)	β-amyloid global SUVR*	β-amyloid centiloid score†	ADAS-Cog score	Clinical dementia rating score	MMSE Score
1	Female	65	HC	341.5	Negative	1.00	−2	5	0	29
2	Female	75	HC	339.7	Negative	0.91	−16	7	0	30
3	Male	61	HC	333.4	Negative	1.00	−1	3	0	30
4	Male	51	HC	347.8	Negative	1.02	2	6	0	29
5	Female	53	HC	353.4	Negative	1.03	3	5	0	29
6	Male	56	HC	347.1	Negative	0.98	−5	2	0	26
7	Male	50	HC	332.6	Negative	1.04	5	6	0	28
8	Male	66	HC	353.4	Negative	1.01	0	9	0	30
9	Male	60	HC	299.0	Negative	1.03	4	3	0	30
10	Female	55	HC	262.7	Negative	0.94	−10	3	0	29
11	Male	58	AD	346.3	Positive	1.99	150	19	0.5	20
12	Female	63	AD	333.4	Positive	1.67	101	16	0.5	28
13	Male	71	AD	335.2	Positive	1.66	100	22	0.5	20
14	Female	63	AD	339.3	Positive	1.83	126	53	2	8
15	Male	70	AD	352.2	Positive	1.66	100	32	0.5	22
16	Male	80	AD	351.1	Positive	1.53	79	14	0.5	17
17	Male	72	AD	343.7	Positive	1.73	111	41	2	8
18	Male	77	AD	336.7	Positive	1.62‡	102	16	0.5	26
19	Male	76	AD	347.4	Positive	1.47	71	13	1	27
20	Female	56	AD	359.6	Positive	1.71	108	22	0.5	23
21	Male	83	AD	349.3	Positive	1.47‡	76	16	0.5	23
22	Female	53	AD	348.2	Positive	1.57	85	25	0.5	23

^*SUVR calculated as described by Klunk et al. (22).

^†Conversion to centiloid score was performed as follows: centiloid score = 153.4 SUVR_FBB – 154.9 (for florbetaben [FBB] (24)); centiloid score = 175 SUVR_FBP – 182 (for forbetapir [FBP] (23)).

^‡Subject scanned with florbetapir.